FDA panel narrowly backs new use of UCB's arthritis drug

[riky]

FDA panel narrowly backs new use of UCB's arthritis drug

(Reuters) - A panel of advisers to the U.S. Food and Drug Administration narrowly recommended approving Belgian drugmaker UCB SA's rheumatoid arthritis drug for an additional indication. FDA advisers voted 7-6, with one abstention, in favor of approving the drug, certolizumab. Eight members of the 14-member panel also said the drug provides a clinically meaningful beneficial effect. One member abstained from voting. The panel unanimously voted in support of the safety profile of the therapy. ...

Source: You are not allowed to view links. Register or Login